Our commitment to better care for patients is demonstrated every day in many ways. Our goal is to better understand the needs of healthcare professionals and to develop relationships that bring greater value to both healthcare professionals and patients. This commitment guides Merck Frosst employees every time they meet healthcare professionals to complement their scientific knowledge and to provide the latest education programs to meet their needs.
This commitment to better care for patients is also always present when we work with the medical community. further advance knowledge of our products through clinical research programs. Patients come first in all our partnerships with our stakeholders including governments and academia.
You, a family member or a friend may have already been helped by a medicine discovered by Merck Frosst and/or our parent company Merck & Co., Inc. Our employees and medicines make a significant contribution to the treatment or prevention of many important conditions, including:
| • |
Asthma |
| • |
Cancer |
| • |
Cardiovascular Diseases |
| • |
High cholesterol |
|
|
| • |
Gastro-duodenal and
gastro-oesophageal reflux |
| • |
Glaucoma |
| • |
Hepatitis A and B |
| • |
HIV/AIDS |
|
|
| • |
Infectious Diseases |
| • |
Male Pattern Baldness |
| • |
Meningitis |
| • |
Measles/Mumps/Rubella |
| • |
Migraine |
|
|
| • |
Osteoporosis |
| • |
Pneumonia |
| • |
Prostate Disease |
| • |
Varicella |
|
|
|
 |
 |
|
|
| The goals of this expedition were to increase awareness of organ donations, promote physical fitness in disease prevention and study the effects of high altitude on transplant recipients. |
|
Merck Frosst Bolivia 6000 team members, from left to right: Dr. Yves Tessier, cardiologist,
St-Sacrement Hospital, Québec City; Sylvain Bédard, heart transplant recipient, Montréal; Dave Smith, kidney transplant recipient, Edmonton; Dr. Heather Ross, cardiologist, Toronto General Hospital; Dr. Michel White, cardiologist, Montreal Heart Institute; and Sébastien Morin, Merck Frosst. |
 |
 |
We are proud of the contribution we make to society, and we look forward to continuing to “discover today for a better tomorrow”. However, Canada needs to foster a favourable environment for innovation and commercialization if more medicines are to be discovered here. Key elements of an innovation environment must include a strong scientific base, a skilled workforce and intellectual property protection. A favourable commercialization environment is built on efficient regulatory reviews, fair pricing and rapid listing for reimbursement on provincial drug plans for innovative products. We work with all levels of government to seek to ensure that these elements are present to improve health in Canada.
FOSAMAX® is a registered trademark of Merck & Co., Inc. Used under license.
COZAAR® is a registered trademark of E.I. du Pont de Nemours and Company, Wilmington,Delaware, U.S.A. Used under license.
